AstraZeneca wins Seroquel XR case in US

LONDON (AP) — AstraZeneca PLC says it has won a judgment in a U.S. court protecting its patent on the extended release version of Seroquel, its blockbuster drug for treating bipolar disorder.

AstraZeneca said Friday that U.S. District Court in New Jersey upheld the formulation patent for Seroquel XR, which expires in 2017.

The company said the court also ruled that Anchen Pharmaceuticals, Inc., Osmotica Pharmaceutical Corp., Torrent Pharmaceuticals Ltd., Torrent Pharma Inc., Mylan Pharmaceuticals Inc. and Mylan Inc. have infringed the patent.

AstraZeneca has also been fighting legal battles to protect its patent on quetiapine, the active ingredient in Seroquel, which expires in December. Seroquel is the company's second-largest-selling brand, accounting for 17 percent of sales last year.

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Reader Comments Read all comments (1)

Add Your Thoughts

Comment Name State Select One AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY International Email

Please enter the two words below into the text field underneath the image.

Incorrect please try again

Enter the words above: Enter the numbers you hear:

Your comment will be posted immediately, unless it is spam or contains profanity. For more information, please see our Comments FAQ.